Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16763522 | 1.00 | MGLL (0.55) | MGLLBACE1PPARGENPP2SYK | |
| SCHEMBL6548418 | 0.88 | PPARG (0.62) | MGLLBACE1PPARGENPP2SYK | |
| SCHEMBL6549737 | 0.88 | PPARG (0.59) | MGLLBACE1PPARGENPP2SYK | |
| SCHEMBL6548407 | 0.88 | PPARG (0.62) | MGLLBACE1PPARGENPP2SYK | |
| SCHEMBL16798202 | 0.86 | MGLL (0.62) | MGLLBACE1PPARGENPP2MAPT | |
| SCHEMBL16798203 | 0.86 | MGLL (0.62) | MGLLBACE1PPARGENPP2MAPT | |
| SCHEMBL14090974 | 0.83 | BACE1 (0.56) | MGLLBACE1PPARGSYKMEN1 | |
| SCHEMBL8183661 | 0.80 | HPGDS (0.50) | PPARG | |
| SCHEMBL8171551 | 0.79 | AKT1 (0.49) | PPARG | |
| SCHEMBL14240829 | 0.79 | CTSK (0.48) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077386-B1 | BENZHYDRYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| CN-105814034-A | Benzhydryl derivatives for the treatment of respiratory diseases | 奇斯药制品公司 | 2016-07-27 | — | — | CN | disclosed |
| US-9145409-B2 | Benzhydryl derivatives | CHIESI FARMACEUTICI S.P.A (IT) | 2015-09-29 | — | — | US | disclosed |
| US-20150158857-A1 | BENZHYDRYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158857-A1 | BENZHYDRYL DERIVATIVES | PDE4A, PDE4B, PDE3A | MGLL 826/4885BACE1 3262/4885PPARG 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.